Joseph Dobson, MD
Family Medicine · Cheyenne, WYNPI 1184645632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $540 and has fallen 66.5% since, to $181 in 2025.
Across 111 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$341
- Novo Nordisk$292
- Vanda Pharmaceuticals Inc.$192
- Amgen$126
- Avanir Pharmaceuticals, Inc.$99
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$89
- plus $869 from 22 others
What the payments were for
- Speaking & faculty fees$171%
- Food & beverage$1,99299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $341 |
| Novo Nordisk | 16 | $292 |
| Vanda Pharmaceuticals Inc. | 12 | $192 |
| Amgen | 7 | $126 |
| Avanir Pharmaceuticals, Inc. | 2 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Johnson & Johnson | 5 | $83 |
| Astellas Pharma US Inc | 5 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Novartis | 4 | $67 |
| AbbVie | 1 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Bayer | 3 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Biogen | 2 | $41 |
| Pfizer | 2 | $40 |
| Alfasigma USA, Inc. | 2 | $37 |
| AstraZeneca | 2 | $36 |
| Biodelivery Sciences International, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $20 |
| GSK | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $10 |
How this compares
$2,008 in reported general payments places this provider in the 85th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 245 | $87,153 |
| XareltoRivaroxaban | 194 | $58,059 |
| OzempicSemaglutide | 38 | $40,915 |
| MounjaroTirzepatide | 33 | $39,908 |
| GemtesaVibegron | 118 | $32,413 |
| FarxigaDapagliflozin Propanediol | 76 | $31,872 |
| RexultiBrexpiprazole | 38 | $27,686 |
| TrulicityDulaglutide | 34 | $25,218 |
| JanuviaSitagliptin Phosphate | 61 | $22,764 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 65 | $20,989 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $13,959 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,460 |
| RybelsusSemaglutide | 12 | $11,432 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $11,350 |
| JardianceEmpagliflozin | 27 | $11,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $40 | $108,142310 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $341 | $68,01196 claims |
| Johnson & JohnsonXarelto | $83 | $58,059194 claims |
| Novo NordiskOzempic, Rybelsus | $292 | $52,34750 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $36 | $40,472109 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $32,413118 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $68 | $27,68638 claims |
| MerckJanuvia | $14 | $22,76461 claims |
| GSKBreo Ellipta | $17 | $11,35025 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $3,16215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Cheyenne
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Douglas EdgrenCheyenne$5K
- Nancy BergquistCheyenne$3K
- Amy HarnishCheyenne$2K
- Gregory StampfliCheyenne$2K
- Samuel HartCheyenne$2K
- Aaron FreemanCheyenne$2K
- Patrick YostCheyenne$1K
- Kimberly BroomfieldCheyenne$971
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.